Literature DB >> 2326392

Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.

T Someya1, S Takahashi, M Shibasaki, T Inaba, S W Cheung, S W Tang.   

Abstract

We measured plasma concentrations of haloperidol (HAL) and its metabolite, reduced haloperidol (RHAL), by high performance liquid chromatography (HPLC) in 45 Japanese psychiatric patients receiving HAL. Plasma levels of HAL had a highly positive correlation with daily dose per body weight. Plasma RHAL/HAL ratios had also a dose-dependent relationship, but their distribution was nonnormal and a bimodal pattern with an antimode at 0.7 was apparent by probit analysis. There were 8 subjects (18%) with high RHAL/HAL ratios (mean = 1.26, SD = 0.41) and 37 subjects (82%) with low RHAL/HAL ratios (mean = 0.42, SD = 0.13). RHAL/HAL ratios showed little intraindividual variability (+/- 10.6%), while interindividual variability was large. This may suggest that pharmacogenetic factors are involved in the metabolism of HAL and RHAL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2326392     DOI: 10.1016/0165-1781(90)90114-k

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

Review 1.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

3.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

4.  Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.

Authors:  D W Eyles; H A Whiteford; T J Stedman; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 6.  Pharmacokinetic optimisation of the treatment of psychosis.

Authors:  A E Balant-Gorgia; L P Balant; A Andreoli
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

7.  Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.

Authors:  D W Eyles; T J Stedman; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.